Cinctive Capital Management LP Buys Shares of 41,849 Bicara Therapeutics Inc. $BCAX

Cinctive Capital Management LP purchased a new position in Bicara Therapeutics Inc. (NASDAQ:BCAX) during the 3rd quarter, Holdings Channel reports. The institutional investor purchased 41,849 shares of the company’s stock, valued at approximately $661,000.

Other large investors have also made changes to their positions in the company. Vestal Point Capital LP lifted its holdings in shares of Bicara Therapeutics by 80.6% during the 2nd quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock valued at $46,450,000 after purchasing an additional 2,231,025 shares during the last quarter. Bank of America Corp DE grew its stake in Bicara Therapeutics by 2,351.0% during the 2nd quarter. Bank of America Corp DE now owns 451,228 shares of the company’s stock worth $4,192,000 after buying an additional 432,818 shares during the last quarter. Artisan Partners Limited Partnership acquired a new position in Bicara Therapeutics during the 2nd quarter valued at about $3,742,000. Schroder Investment Management Group increased its position in Bicara Therapeutics by 921.0% during the 2nd quarter. Schroder Investment Management Group now owns 425,341 shares of the company’s stock valued at $3,951,000 after buying an additional 383,681 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC raised its stake in Bicara Therapeutics by 91.8% in the third quarter. Schonfeld Strategic Advisors LLC now owns 504,085 shares of the company’s stock valued at $7,959,000 after buying an additional 241,334 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on BCAX shares. Wedbush reissued an “outperform” rating and issued a $30.00 price target on shares of Bicara Therapeutics in a report on Tuesday, January 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Friday, January 9th. UBS Group reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. HC Wainwright reiterated a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Finally, Citigroup started coverage on shares of Bicara Therapeutics in a research note on Thursday, January 29th. They set an “outperform” rating on the stock. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $30.25.

Insider Transactions at Bicara Therapeutics

In related news, COO Ryan Cohlhepp sold 17,392 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $18.16, for a total value of $315,838.72. Following the sale, the chief operating officer owned 205,141 shares in the company, valued at $3,725,360.56. This represents a 7.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David Raben sold 16,300 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $18.52, for a total transaction of $301,876.00. Following the completion of the transaction, the insider owned 55,286 shares in the company, valued at approximately $1,023,896.72. This trade represents a 22.77% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 101,269 shares of company stock worth $1,887,703.

Bicara Therapeutics Stock Performance

Bicara Therapeutics stock opened at $19.40 on Tuesday. The business’s 50-day simple moving average is $16.84 and its two-hundred day simple moving average is $16.14. The company has a market cap of $1.06 billion, a PE ratio of -8.66 and a beta of -0.78. Bicara Therapeutics Inc. has a fifty-two week low of $7.80 and a fifty-two week high of $20.25.

Bicara Therapeutics Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.